| Fund ID | 805-8023022373 |
| Fund type | Private Equity Fund |
| 3(c)(1) exclusion | No |
| 3(c)(7) exclusion | Yes |
| Master fund | No |
| Feeder fund | Yes |
| Fund of funds | No |
| Relies on exemption from registration | Yes |
| Annual audit | Yes |
| Prepared per GAAP | Yes |
| Sub-advised | No |
| % of assets independently valued | 100% |
| Owned by the adviser or related persons | 0% |
| Owned by funds of funds | 0% |
| Owned by non-U.S. persons | 83% |
| Fund | Type | Gross assets |
|---|---|---|
| Stone Ridge Opportunities Fund LP | Hedge | $1.46B |
| Stone Ridge Archimedes Master LP | Hedge | $1.27B |
| Stone Ridge Energy Acquisition Fund LP | Hedge | $470.4M |
Drug Royalties Cayman Fund II LP reports $8.7 million in gross assets, among the top 79% of private funds by size.
The stated minimum investment is $100,000.
Drug Royalties Cayman Fund II LP is managed by Stone Ridge Asset Management LLC.
No. Private funds are not required to publicly disclose performance. Form ADV reports assets, structure, and service providers.